MAYRAM ABRAMOV, PHD
Pharmacotherapy Pharmacist in NEW YORK, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What stands out: MAYRAM ABRAMOV, PHD filed 85 Medicare Part D claims in 2023 across NEW YORK, New York. Every figure on this page comes straight from federal CMS records, with no proprietary rating applied.
MAYRAM ABRAMOV, PHD at a glance
Quality data not reportedPrimary specialty
Medicare Part D claims
Specialty distribution in New York
How Pharmacotherapy Pharmacist compares to other specialties among New York providers
Pharmacotherapy Pharmacist share within New York
Pharmacotherapy Pharmacist is one of the more visible NUCC categories in New York
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Specialty board-certification context
Estimated specialty board-certified rate — Pharmacotherapy Pharmacist (ABMS / AOA reference)
- Est. board-certified rate
- 78%
- Pharmacotherapy Pharmacist ABMS/AOA estimate
Est. board-certified rate (Pharmacotherapy Pharmacist) — ABMS / AOA estimate
Verify credentials
- Verify via ABMS free public lookup
- Verify via AOA osteopathic boards
- Specialty volume Pharmacotherapy Pharmacist US NPIs
Specialty board-certified rate — Pharmacotherapy Pharmacist estimate
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus Maintenance of Certification cycles. CMS does not publish a per-provider board-certification field; the figure shown is the specialty-level estimated rate from ABMS / AOA reference data.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
MAYRAM ABRAMOV, PHD is a Pharmacotherapy Pharmacist provider practicing in NEW YORK, New York, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: PHD. NPI: 1033441332. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.
MAYRAM ABRAMOV, PHD appears in the CMS NPPES registry as a Pharmacotherapy Pharmacist provider holding PHD credentials at 773 LEXINGTON AVE, NEW YORK, NY, 10065, with a listed phone of (347) 622-2946. NPI 1033441332 was issued on 02/11/2010. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what ABRAMOV most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 85 prescription claims written by this provider, covering 76 Medicare beneficiaries and totaling roughly $21K in drug spend, split 99% brand-name and 1% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.
Pharmacotherapy Pharmacist is a mid-sized specialty nationwide, with 5,925 enrolled providers across 53 states and an average of 397 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1033441332 |
|---|---|
| Specialty | Pharmacotherapy Pharmacist |
| Credentials | PHD |
| Gender | Female |
| NPI Issued | 02/11/2010 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm MAYRAM ABRAMOV, PHD's current license status, disciplinary history, and board certifications with the New York State Education Department, Office of the Professions in New York before relying on this page for a clinical or care decision.
How we sourced this profile
License & disciplinary context — New York NYSBPMC 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to MAYRAM ABRAMOV, PHD. To verify MAYRAM ABRAMOV, PHD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Brand-heavy
99% brand-name claims vs 1% generic, on 85 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 87
- Total Day Supply
- 174
- Brand vs Generic
- 99% brand / 1% generic
- Brand Drug Cost
- $21K
Patient Demographics
- Average Patient Age
- 71.9 years
- Avg HCC Risk Score
- 0.93
- Gender Split
- 54% female / 46% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
| Drug | Claims |
|---|---|
| Arexvy Rsvpref3 Antigen/As01e/Pf | 44 |
| Shingrix Varicella-Zoster Ge/As01b/Pf | 30 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Pharmacotherapy Pharmacist Overview
How MAYRAM ABRAMOV, PHD fits within the Pharmacotherapy Pharmacist landscape nationally.
MAYRAM ABRAMOV, PHD's 85 claims are below the specialty average of 397.
Nearby Pharmacotherapy Pharmacist Providers in New York
Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as ABRAMOV.
Compare Pharmacotherapy Pharmacist nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore New York
Frequently Asked Questions
What is MAYRAM ABRAMOV, PHD's specialty? ▼
How much does MAYRAM ABRAMOV, PHD prescribe under Medicare Part D? ▼
Where is MAYRAM ABRAMOV, PHD located? ▼
What is MAYRAM ABRAMOV, PHD's NPI number? ▼
Does MAYRAM ABRAMOV, PHD prescribe more brand-name or generic drugs? ▼
How many Pharmacotherapy Pharmacist providers are there in the US? ▼
What drugs does MAYRAM ABRAMOV, PHD prescribe most often? ▼
Does MAYRAM ABRAMOV, PHD accept Medicare? ▼
How can I verify MAYRAM ABRAMOV, PHD's credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology